Cowen Believes Ariad Pharmaceuticals Stock Is Fairly Valued


Cowen’s healthcare analyst Phil Nadeau came out with a research note on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), following the company’s earnings release for the fourth-quarter. The analyst rates the stock a Market Perform with a price target of $4.50, which represents a potential downside of 38% from where the stock is currently trading.

Nadeau noted, “Ariad reported Q4 Iclusig sales consistent with its preannouncement, and provided 2015 Iclusig sales guidance of $130MM-$140MM, in-line with prior consensus of $133MM. Management indicated 2015 will be a year focused on execution as it hopes to expand Iclusig’s use, secure a partner for brigatinib, and complete enrollment in its pivotal trial. We continue to think ARIA is fairly valued.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Phil Nadeau has a total average return of 24.3% and a 75.0% success rate. Nadeau is ranked #188 out of 3479 analysts.